Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part
Poolbeg Pharma (AIM: POLB) secures European patent for POLB 001
Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II
Zak Mir interviews Poolbeg Pharma’s CEO Jeremy Skillington & Principal Scientist Liam Tremble
Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk’s Zak Mir about the company’s conference season.
Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update
ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances in the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.865 million equity raise and a series of high-impact developments across
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances Toward the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.7 million equity raise and a series of high-impact developments across
Poolbeg Pharma PLC (AIM:POLB) Director/PDMR Shareholding
Director Dealing
As AIM marks its 30th anniversary this week, I’ve been reflecting on the five IPOs I’ve led
As AIM turns 30 this week I’ve been reflecting on the 5 IPOs I’ve done on the market since 2012.
Poolbeg Pharma PLC (AIM:POLB) FDA Orphan Drug Designation granted for POLB 001
Poolbeg Pharma PLC (AIM: POLB) has received a significant regulatory endorsement from US authorities for one of its experimental treatments, which aims to address a serious side effect of advanced